Mitchell Foster1, Ian Kamaly-Asl2,3, Stavros Stivaros2,4, Anna Kelsey5, Rao Gattamenini6, John-Paul Kilday7,8. 1. Salford Royal Hospital, Stott Lane, M6 8HD, Salford, England, UK. 2. Children's Brain Tumour Research Network, Royal Manchester Children's Hospital, Oxford Road, M13 9WL, Manchester, England, UK. 3. The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, University of Manchester, Wilmslow Road, M20 4QL, Manchester, England, UK. 4. Academic Unit of Paediatric Radiology, Manchester Academic Health Science Centre, University of Manchester, M13 9WL, Manchester, England, UK. 5. Department of Histopathology Children's Brain Tumour Research Network, Royal Manchester Children's Hospital, Oxford Road, M13 9WL, Manchester, England, UK. 6. Department of Clinical Oncology, Christie Hospital, Wilmslow Rd, Withington, England, UK. 7. Children's Brain Tumour Research Network, Royal Manchester Children's Hospital, Oxford Road, M13 9WL, Manchester, England, UK. John-Paul.Kilday@cmft.nhs.uk. 8. The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, University of Manchester, Wilmslow Road, M20 4QL, Manchester, England, UK. John-Paul.Kilday@cmft.nhs.uk.
Abstract
INTRODUCTION: Histiocytic sarcoma (HS) of the central nervous system (CNS) is exceptionally rare in pediatric patients, historically associated with an exceptionally poor prognosis. Here, the authors present a novel case of protracted progression-free survival following surgical excision, radiotherapy and temozolomide. CASE REPORT: A 15-year-old Caucasian girl presented with a two-month history of headache, diplopia, vomiting, lethargy, weight loss and neurocognitive deterioration without gross neurological deficit on physical examination. Magnetic resonance imaging (MRI) of the brain identified a 5.8 × 4.7 × 4.0 cm lesion in the right frontal lobe with associated mass effect and no dissemination. Following two surgical procedures, gross total resection was achieved. Histology and immunohistochemistry confirmed HS, with strong CD163 staining. After focal radiotherapy with concomitant temozolomide, and a further seven cycles of temozolomide, the patient made an excellent recovery and is recurrence free without neurological deficit, 23 months following presentation. CONCLUSION: To the authors' knowledge, this is the first incidence of a prolonged, functionally preserved and recurrence-free outcome following a diagnosis of HS within the CNS of a pediatric patient. We suggest early diagnosis prior to dissemination and complete surgical resection as an essential treatment goal in this rare disease.
INTRODUCTION: Histiocytic sarcoma (HS) of the central nervous system (CNS) is exceptionally rare in pediatric patients, historically associated with an exceptionally poor prognosis. Here, the authors present a novel case of protracted progression-free survival following surgical excision, radiotherapy and temozolomide. CASE REPORT: A 15-year-old Caucasian girl presented with a two-month history of headache, diplopia, vomiting, lethargy, weight loss and neurocognitive deterioration without gross neurological deficit on physical examination. Magnetic resonance imaging (MRI) of the brain identified a 5.8 × 4.7 × 4.0 cm lesion in the right frontal lobe with associated mass effect and no dissemination. Following two surgical procedures, gross total resection was achieved. Histology and immunohistochemistry confirmed HS, with strong CD163 staining. After focal radiotherapy with concomitant temozolomide, and a further seven cycles of temozolomide, the patient made an excellent recovery and is recurrence free without neurological deficit, 23 months following presentation. CONCLUSION: To the authors' knowledge, this is the first incidence of a prolonged, functionally preserved and recurrence-free outcome following a diagnosis of HS within the CNS of a pediatric patient. We suggest early diagnosis prior to dissemination and complete surgical resection as an essential treatment goal in this rare disease.
Entities:
Keywords:
Central nervous system; Histiocytic sarcoma; Neuro-oncology; Pediatric; Radiotherapy; Temozolomide
Authors: B E Favara; A C Feller; M Pauli; E S Jaffe; L M Weiss; M Arico; P Bucsky; R M Egeler; G Elinder; H Gadner; M Gresik; J I Henter; S Imashuku; G Janka-Schaub; R Jaffe; S Ladisch; C Nezelof; J Pritchard Journal: Med Pediatr Oncol Date: 1997-09
Authors: Jeffrey A Vos; Susan L Abbondanzo; Carol L Barekman; Joann W Andriko; Markku Miettinen; Nadine S Aguilera Journal: Mod Pathol Date: 2005-05 Impact factor: 7.842
Authors: Winnie Wu; Asli Tanrivermis Sayit; Harry V Vinters; Whitney Pope; Leili Mirsadraei; Jonathan Said Journal: Hum Pathol Date: 2013-01-26 Impact factor: 3.466
Authors: Jackson M May; Mark R Waddle; Daniel H Miller; William C Stross; Tasneem A Kaleem; Byron C May; Robert C Miller; Liuyan Jiang; Gerald W Strong; Daniel M Trifiletti; Kaisorn L Chaichana; Ronald Reimer; Han W Tun; Jennifer L Peterson Journal: Radiat Oncol Date: 2018-09-05 Impact factor: 3.481